- Home
- CERO vs GRI Comparison
CERO vs GRI Comparison
Compare CERO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- GRI
- Stock Information
- Founded
- CERO 2017
- GRI 2018
- Country
- CERO United States
- GRI United States
- Employees
- CERO N/A
- GRI N/A
- Industry
- CERO
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- GRI Health Care
- Exchange
- CERO Nasdaq
- GRI Nasdaq
- Market Cap
- CERO 3.5M
- GRI 3.4M
- IPO Year
- CERO N/A
- GRI N/A
- Fundamental
- Price
- CERO $7.50
- GRI $2.14
- Analyst Decision
- CERO Strong Buy
- GRI Strong Buy
- Analyst Count
- CERO 2
- GRI 2
- Target Price
- CERO $45.00
- GRI $22.00
- AVG Volume (30 Days)
- CERO 95.7K
- GRI 176.5K
- Earning Date
- CERO 08-13-2025
- GRI 08-13-2025
- Dividend Yield
- CERO N/A
- GRI N/A
- EPS Growth
- CERO N/A
- GRI N/A
- EPS
- CERO N/A
- GRI N/A
- Revenue
- CERO N/A
- GRI N/A
- Revenue This Year
- CERO N/A
- GRI N/A
- Revenue Next Year
- CERO N/A
- GRI N/A
- P/E Ratio
- CERO N/A
- GRI N/A
- Revenue Growth
- CERO N/A
- GRI N/A
- 52 Week Low
- CERO $6.71
- GRI $1.10
- 52 Week High
- CERO $895.40
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- CERO 40.75
- GRI 67.16
- Support Level
- CERO $7.27
- GRI $1.93
- Resistance Level
- CERO $8.83
- GRI $2.10
- Average True Range (ATR)
- CERO 0.43
- GRI 0.18
- MACD
- CERO -0.06
- GRI 0.03
- Stochastic Oscillator
- CERO 13.14
- GRI 91.58
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.